AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03237897 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pedometer
Description: A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
Study NCT00823238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftazidime and tobramycin
Study NCT00823238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled tobramycin
Study NCT05225545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial Iron
Description: Experimental Arm
Study NCT05225545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Active Comparator
Study NCT02667301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG recording
Description: 1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
Study NCT02667301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanic Cavity Air Exchange Test
Description: Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
Study NCT02667301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanometer test
Description: Patient is subjected to tympanometry test on the specific ear and information is recorded.
Study NCT01148394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal rehabilitation
Study NCT01148394 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Multimodal rehabilitation
Study NCT05282368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHM™ Pathway
Description: The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell \| Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell \| Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items.
Study NCT02283658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT02283658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02283658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT04087837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bougie
Description: The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
Study NCT04087837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasogastric(NG) tube
Description: The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
Study NCT04201236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory muscle strengthening exercise
Description: These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.
Study NCT04201236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oropharyngeal muscles strengthening exercise
Description: These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
Study NCT00807365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHRH
Description: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
Study NCT00490971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
Study NCT00490971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
Study NCT00490971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
Study NCT00593450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: • 0.5 mg (0.05 mL)intravitreal injection
Study NCT00593450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: • 0.5 mg (0.05 mL)intravitreal injection
Study NCT00593450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: • 1.25 mg (0.05 mL)intravitreal injection
Study NCT00642408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMN)
Description: Iron and folic acid: iron 60 mg and folic acid 400µg
Study NCT00642408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA
Description: Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
Study NCT00820170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib and Paclitaxel
Description: A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel.
Study NCT02531555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 810 Nanometer Wavelenght GaAlAs Diode Laser
Description: FDA approved 810 nanometer GaAlAs Diode Laser
Study NCT02531555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey curettes
Study NCT02531555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gracey curettes
Study NCT00902746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-01
Description: This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point.
Study NCT01681121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-N05
Description: 150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
Study NCT01681121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
Study NCT04113642 — intervention group
Intervention type: OTHER
Intervention: ultrasonographic measurement of abdominal muscle thickness at four positions
Description: Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
Study NCT00968071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 IV over an hour and half daily for 5 days.
Study NCT00968071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: 3 mg/m\^2 IV on day 5.
Study NCT02765334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nBETTER
Description: 60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
Study NCT04372862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plane block
Description: Two different plane blocks to control post-mastectomy pain
Study NCT01516619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8.
Study NCT00484484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine
Study NCT00691587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001
Description: Single low-dose, administered intravenously
Study NCT00691587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB001
Description: Single high-dose, administered intravenously
Study NCT00691587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single-dose, administered intravenously
Study NCT01277887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Counseling
Description: The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
Study NCT01277887 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
Study NCT04521751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-02 120 mg orlistat/40 mg acarbose
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
Study NCT04521751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-02 150 mg orlistat/50 mg acarbose
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
Study NCT04521751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo capsules
Study NCT01521936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO (lower dose)
Study NCT01521936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01521936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO (higher dose)
Study NCT01521936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01266551 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: car safety seat
Description: The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
Study NCT04025489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Randomized control trial of vitamin D supplementation
Description: This open-label randomized placebo-controlled prospective trial will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. Anthropometry, body composition, levels of vitamin D, blood glucose (including oral glucose tolerance test) and dietary assessments will be assessed periodically (every 3 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. Diet and exercise will be recommended as per the regular norms for overweight and obese subjects. Clinical and dietary profile, sunlight exposure, glycemic and lipid profile other metabolic parameters, body composition, hand grip strength, leukocyte telomerase length and telomerase activity will be assessed at enrolment time and one-year intervention. As mentioned above, genes related to ageing will be evaluated. Effects on polymorphisms of pro-ageing genes will be assessed.
Study NCT02297100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A
Description: 100 units of botox spread out among 10 separate injections
Study NCT01941394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells infusion
Study NCT02007720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Intravenous infusion
Study NCT02007720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT02007720 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of CareTherapy
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Study NCT02007720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of CareTherapy
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Study NCT00082212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
Study NCT04019145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EverX Posterior
Description: fiber reinforced bulk fill resin composite
Study NCT04019145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resins, Composite
Description: incremental packing of Nanohybrid Resin composite
Study NCT01369459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIP Protocol
Description: We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
Study NCT02193204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Stress Imagery
Description: The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
Study NCT02193204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Imagery
Description: The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
Study NCT03510975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin melt form 120 μg
Description: desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
Study NCT03510975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal behavioral therapy
Description: Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
Study NCT03510975 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Verbal behavioral therapy
Description: Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
Study NCT03510975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy with written check-list
Description: Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
Study NCT02455505 — intervention group
Intervention type: BEHAVIORAL
Intervention: background questionnaire
Study NCT02455505 — intervention group
Intervention type: BEHAVIORAL
Intervention: bereavement risk screening tool
Study NCT03233815 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Propofol anesthesia Dose: 4-6mg/kg/h
Study NCT03233815 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
Study NCT02090686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile Cupping
Description: 8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)
Study NCT02090686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Cupping
Description: 8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
Study NCT02546869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
Study NCT02546869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Syringes
Study NCT02574663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202 oral daily dose
Study NCT02574663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel + gemcitabine
Description: IV infusion
Study NCT02574663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Folinic acid + Fluorouracil
Description: IV infusion
Study NCT02574663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab
Description: IV Infusion
Study NCT03654729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir (2 µmol/kg)
Description: Solution in 20 mL single dose glass vials
Study NCT03654729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir (5 µmol/kg)
Description: Solution in 20 mL single dose glass vials
Study NCT03654729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution in 20 mL single dose glass vials
Study NCT03169478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multiple myoma IUB dilatation group
Description: A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.